Dr. Puri has reported that he has no relationships relevant to the contents of this paper to disclose.
T1, but not compared with T2. The 24% mortality rate of the T3 population at 2 years post-TAVR (compared with the 35% corresponding mortality rate of the T1 population) was then placed into perspective by the authors, who compared these results with the 2-year mortality data from the inoperable (43%) and high-risk transfemoral (31%) PARTNER cohorts.
So, does the totality of this data equate to a real evolution in TAVR? Some caveats of the analysis by It is therefore reassuring to observe, within the confines of the PARTNER nonrandomized continuedaccess study, the evolution of TAVR and its favorable effect on outcomes in a relatively short space of time. arise following ongoing refinement in patient selection. Integrating TAVR-related risk scores during patient evaluation (13) (14) (15) , which are likely to be further improved by incorporating measures of frailty (9), will contribute toward improving the outlook of patients undergoing TAVR.
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